|
Name |
Fumiquinazoline F
|
Molecular Formula | C21H18N4O2 | |
IUPAC Name* |
(1S,4R)-4-(1H-indol-3-ylmethyl)-1-methyl-2,4-dihydro-1H-pyrazino[2,1-b]quinazoline-3,6-dione
|
|
SMILES |
C[C@H]1C2=NC3=CC=CC=C3C(=O)N2[C@@H](C(=O)N1)CC4=CNC5=CC=CC=C54
|
|
InChI |
InChI=1S/C21H18N4O2/c1-12-19-24-17-9-5-3-7-15(17)21(27)25(19)18(20(26)23-12)10-13-11-22-16-8-4-2-6-14(13)16/h2-9,11-12,18,22H,10H2,1H3,(H,23,26)/t12-,18+/m0/s1
|
|
InChIKey |
SUVZUTHVKIBYOH-KPZWWZAWSA-N
|
|
Synonyms |
FUMIQUINAZOLINE F; CHEBI:64550; (1S,4R)-4-(1H-indol-3-ylmethyl)-1-methyl-2H-pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione; (?)-Fumiquinazoline F; CHEMBL2229117; DTXSID30891847; C22145; Q27133342; (1S,4R)-4-(1H-indol-3-ylmethyl)-1-methyl-2,4-dihydro-1H-pyrazino[2,1-b]quinazoline-3,6-dione; 169626-35-1
|
|
CAS | 169626-35-1 | |
PubChem CID | 10089772 | |
ChEMBL ID | CHEMBL2229117 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 358.4 | ALogp: | 2.5 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 77.6 | Aromatic Rings: | 5 |
Heavy Atoms: | 27 | QED Weighted: | 0.574 |
Caco-2 Permeability: | -4.924 | MDCK Permeability: | 0.00000719 |
Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.146 |
30% Bioavailability (F30%): | 0.265 |
Blood-Brain-Barrier Penetration (BBB): | 0.557 | Plasma Protein Binding (PPB): | 94.28% |
Volume Distribution (VD): | 1.359 | Fu: | 3.46% |
CYP1A2-inhibitor: | 0.369 | CYP1A2-substrate: | 0.458 |
CYP2C19-inhibitor: | 0.903 | CYP2C19-substrate: | 0.221 |
CYP2C9-inhibitor: | 0.818 | CYP2C9-substrate: | 0.83 |
CYP2D6-inhibitor: | 0.51 | CYP2D6-substrate: | 0.634 |
CYP3A4-inhibitor: | 0.932 | CYP3A4-substrate: | 0.614 |
Clearance (CL): | 4.372 | Half-life (T1/2): | 0.281 |
hERG Blockers: | 0.054 | Human Hepatotoxicity (H-HT): | 0.916 |
Drug-inuced Liver Injury (DILI): | 0.924 | AMES Toxicity: | 0.312 |
Rat Oral Acute Toxicity: | 0.651 | Maximum Recommended Daily Dose: | 0.89 |
Skin Sensitization: | 0.097 | Carcinogencity: | 0.35 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.028 |
Respiratory Toxicity: | 0.686 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005478 | 1.000 | D0BV3J | 0.351 | ||||
ENC003272 | 0.615 | D0G9YH | 0.350 | ||||
ENC004267 | 0.582 | D02DMQ | 0.345 | ||||
ENC002127 | 0.569 | D04VKS | 0.342 | ||||
ENC004931 | 0.536 | D02TJS | 0.330 | ||||
ENC003666 | 0.534 | D0B1FE | 0.330 | ||||
ENC002940 | 0.531 | D08FTG | 0.323 | ||||
ENC006010 | 0.515 | D0QV5T | 0.314 | ||||
ENC001912 | 0.510 | D0E3OF | 0.312 | ||||
ENC004934 | 0.510 | D05EJG | 0.304 |